Stay updated with breaking news from Guidelines Panel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Previously, Robert Califf previewed his priorities, if confirmed, to the Senate HELP Committee.
A daily roundup of news on COVID-19 and the rest of medicine
A combination of remdesivir and a concentrated solution of antibodies did not work well in people hospitalized with COVID-19, ...
WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has revised the authorizations for two monoclonal antibody treatments - bamlanivimab and etesevimab (administered together) and REGEN-COV
The U.S. Food and Drug Administration has subtracted a pair of COVID-19 monoclonal antibody treatments from the approved list due to what the agency has deemed "ineffectiveness" against the Omicron variant, which has spread rapidly throughout the U.S. and the world. Bamlanivimab and etesevimab, which are administered in tandem, and REGEN-COV are no longer authorized for use,